Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976334 | 0.80 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6970103 | 0.80 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1936077 | 0.80 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL894571 | 0.80 | — | — | |
| SCHEMBL63548 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL3279117 | 0.78 | HPGD (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1936476 | 0.78 | HPGD (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1950482 | 0.78 | HPGD (0.59) | HTR6HPGDKMT2ASMN1; SMN2CHRNB2 | |
| Hydrochloric Acid SCHEMBL64625 | 0.78 | HPGD (0.59) | HTR6HPGDKMT2ASMN1; SMN2CHRNB2 | |
| Ammonia Solution, Strong SCHEMBL19410292 | 0.78 | HPGD (0.53) | HTR6HPGDKMT2ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | HTR6 752/4885HPGD 28/4885KMT2A 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.